Librela for dogs: evidence, safety, and FDA status

Bottom line: Librela (bedinvetmab injection) is FDA approved for the control of pain associated with osteoarthritis in dogs. FDA approval relied on two field studies with mixed results at the prespecified Day 28 endpoint, and the current label includes important post-approval neurologic, urinary, gastrointestinal, musculoskeletal, and other reported adverse events. This record does not determine whether Librela is appropriate for an individual dog.

Educational information only. This record does not diagnose osteoarthritis, choose a treatment, reproduce a dose, or replace a veterinarian’s assessment of a dog’s history, examination, other medicines, and monitoring needs.

1. Treatment and scope

This record covers Librela, the brand name for bedinvetmab injection, for the FDA-defined use of controlling pain associated with osteoarthritis in dogs. The official labeling describes a canine monoclonal antibody injection restricted to use by or on the order of a licensed veterinarian.

The scope does not silently extend to cats, other species, pain from an undiagnosed cause, a compounded preparation, or an extra-label decision. A veterinarian may need to establish what is causing a dog’s signs before this record is relevant.

2. Regulatory status

FDA approved — defined scope: The FDA announced approval of Librela on May 5, 2023, for the control of pain associated with osteoarthritis in dogs. The approval is NADA 141-562. The status was checked against the FDA approval notice, approval summary, and current package insert on August 21, 2026.

FDA approval is not a universal suitability, safety, superiority, or outcome guarantee. It also does not make a human product, another species’ use, or an online claim equivalent to the approved dog indication.

3. Evidence stage

FDA-reviewed target-species evidence: FDA evaluated two randomized, masked, placebo-controlled field studies—272 dogs in the United States and 287 dogs in Europe.

At the prespecified Day 28 primary endpoint, the European study showed a statistically significant difference in treatment success, but the U.S. study did not. By Day 42, after the second monthly injection, more Librela-treated dogs than control dogs were treatment successes in both studies. FDA used the combined weight of evidence from the two studies to support approval when Librela is given as a minimum of two doses administered one month apart.

The pivotal studies used an owner-reported pain-and-function measure and controlled follow-up lasted 84 days. A single-arm, open-label continuation followed 89 dogs for six additional months without a control group. These design limits, outcome definitions, enrollment criteria, exclusions, and the difference between a study endpoint and an individual owner’s treatment goal matter when interpreting the findings.

4. Benefits, limits, and safety

The supported clinical question is control of pain associated with osteoarthritis. It is not a claim that Librela repairs a joint, treats every cause of reduced mobility, or produces the same response in every dog.

The current label says Librela should not be administered to dogs with known hypersensitivity to bedinvetmab and should not be used in breeding, pregnant, or lactating dogs. The client information sheet says dogs younger than 12 months should not receive it. Safe use with concurrent NSAIDs has not been established. Long-term effects more than nine months after use have not been evaluated, and long-term effects in dogs with cardiac disease are unknown.

Post-approval reports listed in the January 2025 label include neurologic events such as ataxia, seizures, paresis, proprioception deficits, and paralysis; general events including anorexia, lethargy, and recumbency; urinary events including increased drinking, increased urination, and urinary incontinence; vomiting and diarrhea; and musculoskeletal events including weakness, tremors, and lameness. In some reports, death or euthanasia was an outcome. These reports are important safety signals, but voluntary reports cannot reliably establish how frequently an event occurs or whether Librela caused a particular event.

FDA also published a veterinarian communication regarding reported adverse events after Librela use. Owners should receive and review the current Client Information Sheet with their veterinarian before every injection and contact the veterinarian about new balance problems, trouble walking or standing, weakness, paralysis, seizures, urinary changes, vomiting, diarrhea, or other concerning changes.

5. Cost data status

No treatment-price range is published yet. This page currently explains cost components only.

It will be updated when the Index has enough source-dated, location-labeled observations to show a clearly limited sample without implying a national or typical price.

Until then, request an itemized estimate that separates the examination, diagnostics, drug or administration, monitoring, repeat visits, and other care. A single product, dose, or visit price is not necessarily the complete cost of treatment.

6. Insurance status and variables

Insurance is a separate contract question. Read Does Pet Insurance Cover Librela? The 4 Policy Tests for policy timing, pre-existing-condition, benefit-category, invoice, and claim-review questions; this Treatment Record does not determine whether a claim is covered.

7. Legitimate access

The official label states that federal law restricts the product to use by or on the order of a licensed veterinarian. A legitimate next step is a veterinary evaluation and an itemized discussion of the diagnosis, administration, monitoring, alternatives, and expected reassessment—not an online purchase claim or a dosing guide.

8. Established alternatives

Depending on the diagnosis and patient factors, a veterinarian may discuss other pain-management medicines, rehabilitation, activity or home-environment changes, weight management, supportive care, referral, or a different treatment plan. This record does not rank those options or imply that one is right for every dog.

9. Appropriate next step

If a veterinarian has raised Librela, ask:

• What diagnosis and treatment goal are we addressing?
• What benefit will we measure, and when will we reassess?
• What current medicines, health conditions, or prior responses affect the discussion?
• What are the complete expected costs and repeat-visit requirements?
• What warning signs or changes should prompt a call?
• Which established alternatives belong in the same comparison?

Sources and claim verification

1. FDA approval notice for Librela — supports the May 5, 2023 FDA approval and the defined dog osteoarthritis-pain indication; checked August 18, 2026.
2. FDA FOI Summary for the Original Approval, NADA 141-562 — supports the May 5, 2023 approval date, approved dog indication, two pivotal field studies, mixed Day 28 results, and FDA’s weight-of-evidence conclusion; checked August 21, 2026.
3. Librela package insert — supports product description, dog-only labeling, prescription restriction, administration context, warnings, precautions, and reported adverse reactions; label checked August 18, 2026.
4. Randomized clinical study in client-owned dogs — supports the study design and target-species population described in the evidence section; published 2021; checked August 18, 2026.
5. FDA veterinarian communication about Librela adverse events — supports the FDA’s reported neurologic, urinary, and other adverse-event categories, including reports where death or euthanasia was an outcome; checked August 19, 2026.

Change log

• August 19, 2026: Added both pivotal field studies and the mixed Day 28 result; added the FDA safety communication and January 2025 label information; and expanded restrictions, evidence limitations, and post-approval safety information.
• August 21, 2026: Replaced a non-loading FDA FOI link with the FDA-linked original approval FOI summary. No substantive treatment conclusion changed.